National Centre for Asbestos Related Diseases

Improving treatment outcomes for malignant mesothelioma patients using biomarkers

Further Information

  • All current grants
  • All previous grants

Our aims are:

  1. To evaluate the diagnostic sensitivity and specificity. We will examine fibulin-3, FAM3C, HNRPU, MPF, calretinin by available ELISA assays in the test set of samples, and will pursue independent funding to perform the valdatio studies.
  2. To evaluate the use of serum biomarkers in monitoring MM tumour progression/regression: From the NHMRC application we will concentrate on evaluating biomarkers in samples from patients being treated by chemotherapy regimes as these patients become available and to relate changes in serum biomarker levels to changes by simple statistical correlations to CT scan measures, rather than the development of complex algorithms.
  3. To evaluate candidate biomarkers for the early detection of MM in asbestos-exposed individuals. Similar to Aim 2, the important issue is to capture available patients as they become available for study.

Back to top


National Centre for Asbestos Related Diseases

This Page

Last updated:
Wednesday, 18 November, 2015 2:59 PM